- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
XLKD1 Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP2015a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
XLKD1 Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | Q9Y5Y7 |
| Other Accession | NP_006682 |
| Clone Names | 2120912 |
| Calculated MW | 35213 Da |
XLKD1 Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 10894 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP2015a was selected from the N-term region of human XLKD1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
XLKD1 Antibody (N-term) Blocking Peptide - Protein Information | |
| Name LYVE1 | |
| Synonyms CRSBP1, HAR, XLKD1 | |
| Function Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as a hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes | |
| Cellular Location Membrane; Single-pass type I membrane protein. Note=Localized to the plasma membrane and in vesicles near extranuclear membranes which may represent trans-Golgi network (TGN) and endosomes/prelysosomeal compartments. Undergoes ligand-dependent internalization and recycling at the cell surface | |
| Tissue Location Mainly expressed in endothelial cells lining lymphatic vessels | |
XLKD1 Antibody (N-term) Blocking Peptide - Related products
AP2015a: XLKD1 Antibody (N-term)
AP2015b: LYVE1 (XLKD1) Antibody (C-term)
RI13109: LYVE1 predesign siRNA
LY11851a: LYVE1 Over-expression Lysate
XLKD1 Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
One of the key groups of molecules regulating leukocyte and tumour cell migration is the glycosaminoglycan hyaluronan (HA). In inflammation, the exit of leukocytes across vascular endothelium to the underlying tissues involves interactions with cell surface lectin-like receptors on the leukocytes that bind HA on the lumenal surface of the endothelium. During normal tissue homeostasis and after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. Lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 is a major receptor for HA on the lymph vessel wall. LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumour cells to lymph nodes.
REFERENCES
Jackson, D.G., Trends Cardiovasc. Med. 13(1):1-7 (2003).Cursiefen, C., et al., Invest. Ophthalmol. Vis. Sci. 43(7):2127-2135 (2002).Cunnick, G.H., et al., Biochem. Biophys. Res. Commun. 288(4):1043-1046 (2001).Mouta Carreira, C., et al., Cancer Res. 61(22):8079-8084 (2001).Banerji, S., et al., J. Cell Biol. 144(4):789-801 (1999).
